• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Sonus announces stock offering

Article

Ultrasound contrast agent developer Sonus Pharmaceutical lastweek announced its plan to become a public company. The Bothell, WA, firm filed with the Securities and ExchangeCommission for an initial public offering of up to 2.5 millioncommon shares.

Ultrasound contrast agent developer Sonus Pharmaceutical lastweek announced its plan to become a public company.

The Bothell, WA, firm filed with the Securities and ExchangeCommission for an initial public offering of up to 2.5 millioncommon shares. Proceeds from the offering, to be made at $10 to$12 a share, will support ongoing R&D activities.

Sonus has completed phase II clinical testing of EchoGen, amicrobubble ultrasound contrast agent potentially useful in echocardiographyand perfusion procedures. It plans to file a new drug applicationwith the Food and Drug Administration by April 1, 1996.

Recent Videos
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Related Content
© 2025 MJH Life Sciences

All rights reserved.